The American Urological Association (AUA) and Society of Urologic Oncology (SUO) released an update to their guideline on Early Detection of Prostate Cancer. This update replaces the previous version, published in April of 2023. This guideline update integrates newly published literature and the recommendations discuss early detection of prostate cancer to provide a framework to facilitate clinical decision making in prostate cancer screening and follow-up.
Since the 2023 guideline, changes were made to recommendations on the sections on initial biopsy, repeat biopsy, and biopsy technique.
While this guideline is comprehensive, this article will only review a small portion of the available information, we encourage you to view the full guideline at the summary and full-text links below for more information on this topic.
Guidelines Referenced:
- Early Detection of Prostate Cancer
- Publication: April 2023
- Full Text
Major Changes in the 2026 Guideline
Initial Biopsy
- Clinicians may use magnetic resonance imaging (MRI) prior to initial biopsy to increase the detection of Grade Group (GG)2+ prostate cancer. This recommendation was upgraded from Evidence Level: Grade B to Grade A.
Repeat Biopsy
- In patients with atypical small acinar proliferation (ASAP), clinicians should perform additional testing, which may include repeat biopsy. This recommendation was upgraded from Expert Opinion to Moderate Recommendation; Evidence Level: Grade C.
Biopsy Technique
- Clinicians may use either a transrectal or transperineal biopsy route when performing a biopsy. This recommendation was upgraded from Evidence Level: Grade C to Grade B.
Sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2026, Guideline Central, All Rights Reserved.